Related Experiment Video
Updated: Sep 24, 2025

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
Published on: September 20, 2024
Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma
Johnathan Kent1, Philip Erwin1, Daniel Haraf2
1Department of Surgery, University of Chicago, Chicago, Illinois.
Abstract:
Anaplastic thyroid carcinoma is a rare but aggressive neoplasm that often presents as advanced inoperable disease. Patients with B-Raf proto-oncogene (BRAF) v600e mutated anaplastic thyroid carcinoma who receive neoadjuvant dabrafenib/trametinib have improved rates of microscopically margin-negative resection and durable locoregional control. However this has not been evaluated in the setting of tracheal resection and primary reconstruction. Here we demonstrate the safety and efficacy of laryngotracheal resection and reconstruction after dabrafenib/trametinib for locoregionally advanced BRAF v600e mutated anaplastic thyroid carcinoma.

